Frank Cichocki,Ryan Bjordahl,Jodie P. Goodridge,Sajid Mahmood,Svetlana Gaidarova,Ramzey Abujarour,Zachary B. Davis,Aimee Merino,Katie Tuininga,Hongbo Wang,Akhilesh Kumar,Brian Groff,Alec Witty,Greg Bonello,Janel Huffman,Thomas Dailey,Tom T. Lee,Karl-Johan Malmberg,Bruce Walcheck,Uta Höpken,Armin Rehm,Bahram Valamehr,Jeffrey S. Miller

Abstract:Abstract Allogeneic natural killer (NK) cell adoptive transfer is a promising treatment for several cancers but is less effective for the treatment of multiple myeloma. In this study, we report on quadruple gene-engineered induced pluripotent stem cell (iPSC)-derived NK cells designed for mass production from a renewable source and for dual targeting against multiple myeloma through the introduction of an NK cell-optimized chimeric antigen receptor (CAR) specific for B cell maturation antigen (BCMA) and a high affinity, non-cleavable CD16 to augment antibody-dependent cellular cytotoxicity when combined with therapeutic anti-CD38 antibodies. Additionally, these cells express a membrane-bound interleukin-15 fusion molecule to enhance function and persistence along with knock out of CD38 to prevent antibody-mediated fratricide and enhance NK cell metabolic fitness. In various preclinical models, including xenogeneic adoptive transfer models, quadruple gene-engineered NK cells consistently demonstrate durable antitumor activity independent of exogenous cytokine support. Results presented here support clinical translation of this off-the-shelf strategy for effective treatment of multiple myeloma.

Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma